The stock is trying to settle below $55.50.
Shares of Novavax moved to yearly lows after Japanese Health Ministry committee approved the company’s coronavirus vaccine.
While the news is positive for Novavax, the market believes that the company is “late to the party”. The world’s focus is moving away from the coronavirus pandemic, and it remains to be seen whether vaccines will enjoy strong demand in 2023 and beyond.
Shares of other vaccine makers are also under pressure during the current trading session. Moderna stock is down by 4%, while BioNTech stock is down by almost 7%.
It should be noted that recent reports about a potential waiver of intellectual property rights for coronavirus vaccines and treatments also put pressure on vaccine-related stocks.
Analysts expect that Novavax will report earnings of $22.84 per share in the current year and earnings of $14.36 per share in the next year, so the stock is trading at just 4 forward P/E.
However, analyst estimates have declined materially in recent months, and traders are worried that they could move lower. In addition, it is not clear whether demand for coronavirus vaccines will stay strong in the upcoming years.
Earnings visibility is a problem for all vaccines makers, but Novavax stock is under more pressure as the company’s vaccine has lost competition for market share.
In this light, it remains to be seen whether speculative traders will try to “catch the falling knife” and buy Novavax stock at yearly lows. At this point, it looks that the stock has a good chance to develop additional downside momentum in the upcoming trading sessions.
For a look at all of today’s economic events, check out our economic calendar.
Vladimir is an independent trader, with over 18 years of experience in the financial markets. His expertise spans a wide range of instruments like stocks, futures, forex, indices, and commodities, forecasting both long-term and short-term market movements.